The PennZone

  • Home
  • Business
  • Construction
  • Entertainment
  • Health
  • Technology
  • Travel
  • Real Estate
  • Marketing

Actuated Medical Developing Technology to Improve Targeting for Next-Generation Alcohol Use Disorder Treatments
The PennZone/10278266

Trending...
  • Actress/Model Raelia Lewis Building a Powerful Name in Entertainment and Fashion
  • Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
  • GDE Tree Services Expands Operations into Sydney, NSW
Actuated Medical Inc.
BELLEFONTE, Pa. - PennZone -- Treating alcohol misuse remains a major challenge worldwide.  Given the diverse biological processes that contribute to alcohol use disorder, new medications are needed to provide a broader spectrum of treatment options. Some people may respond to a medication that helps with craving, others may respond to a medication that relieves impulsivity, others may respond to a medication that reverses the negative emotional state of withdrawal or protracted withdrawal. Just like any other medical condition, people with alcohol use disorder deserve to have a range of treatment options available to them. Scientists are working to develop a larger menu of pharmaceutical treatments that could be tailored to individual needs.

Actuated Medical's innovative NeuralGlider Injector will enable the delivery of next-generation medications into small targets deep in the brain, to fundamentally change the trajectory of alcohol use disorder and improve outcomes.  The goal is to deliver a therapeutic that will damp down cravings enough for other therapies to have a chance to work.  The therapeutic gets delivered accurately to the target and stays there.

Actuated Medical, Inc. has been awarded a $3 million pre-clinical Phase II Small Business Innovative Research (SBIR) grant from the National Institutes of Health-National Institute on Alcohol Abuse and Alcoholism to develop the "Oscillated Insertion Tool for Minimally Invasive, Low-Damage, Accurate Placement of Delivery Cannula to Improve Efficacy for DREADDS (designer receptors exclusively activated by designer drugs) Therapy in Alcohol Addiction Treatment" which will be commercially recognized as the NeuralGlider Injector.

More on The PennZone
  • Deborah E. Jones Introduces Emotional Sovereignty, a Powerful New Book on Emotional Mastery, Resilience, and Intentional Living
  • New Research Identifies "The Busy Effect": 89% of Americans Want a Laid-Back Vacation — Only 15% Actually Achieve It
  • Alchemy 43 Appoints Shane Smith as CEO to Drive Operational Performance and Scalable Growth
  • Best Spiritual Healing, Meditation & Retreats in Sedona — Rise Meditation Helps You Find and Book Transformational Experiences
  • $16 Billion Market by 2034 in Underwater Drones Presents Huge Opportunity for AI-Powered Autonomous Vehicle Serving Defense & Commercial Customers

"Many of us know someone who is dealing with an alcohol addiction and have felt helpless as we watched them suffer. That is why we are so excited to develop and commercialize our NeuralGlider Injector technology as it may one day help to offer a more effective treatment option for those afflicted with alcohol use disorder." Maureen L. Mulvihill, Ph.D., Actuated Medical President, CEO, & Co-Founder.

About Actuated Medical, Inc.

Actuated Medical is a Pennsylvania medical device product innovator founded in 2006 on the entrepreneurial idea that electronically controlled motion can solve clinical needs and improve patient outcomes. They are developing products in the areas of neuroscience, critical care, gastroenterology, and pediatrics. Their Actuated Neuroscience Division focuses on developing tools to assist researchers in understanding neurological conditions. Recently, they were awarded a 5-year Contract under the National Institutes of Health (NIH) Blueprint MedTech (BPMT) initiative to assist brain researchers conduct their FDA compliant testing. Actuated has 42 issued patents and 7 FDA 510(k) clearances. They have been the recipient of a 2014 & 2020 SBA Tibbets Awards for SBIR commercialization excellence. Actuated's CEO was the 2020 Life Sciences Pennsylvania CEO of the Year due to the teams Covid PPE pivot.

More on The PennZone
  • Appliance EMT Named Among Jacksonville's Top 3 Appliance Repair Companies by ThreeBestRated®
  • The Scratch-Off Dead Zone - is your state lottery failing?
  • Geekstorians Nominated For Best History Podcast In The 30th Annual Webby Awards
  • Quality Water Treatment Unveils SoftPro Elite HE Water Softener for City Water, Setting a New Standard in Residential Water Treatment
  • UK Financial Ltd Chooses PUMP.FUN App to Launch Maya Meme's Minor-League Meme Coins and Announces Lifetime Airdrop Program

More information about Actuated neural device innovations.

See www.actuatedneuroscience.com

NIH Disclaimer.

Research reported in this publication was supported by the National Institute On Alcohol Abuse And Alcoholism of the National Institutes of Health under Award Number R44AA030512. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

###

For more information about this topic, please contact Maureen L. Mulvihill, Ph.D. by phone at 814-355-0003 or email at info@actuatedmedical.com.

Additional information can be found by visiting:

https://actuatedmedical.com

https://actuatedneuroscience.com

Contact
Actuated Medical
***@actuatedmedical.com


Source: Actuated Medical, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
  • Tyler G. Hicks' Encyclopedia of Wealth Building Secrets Released in a Powerful New Edition
  • Just 1 in 57 Crypto Owners Globally Pay Taxes on Their Holdings, New Report Finds
  • New Book Gives Technology Leaders the Blueprint to Drive Real, Lasting Impact
  • IQSTEL accelerates toward profitability inflection with $317M revenue and AI-driven expansion; IQSTEL Inc. (N A S D A Q: IQST) i
  • AI-Driven Breakthrough Unleashed: Bionic Intelligence Platform Goes Live to Capture Massive Biotech Opportunity: KALA BIO, Inc. (N A S D A Q: KALA)
  • Surging Into Hyper-Growth Mode With Record Revenue, Raised 2026 Guidance, and Game-Changing AI Platform; Off The Hook YS (NYSE American: OTH)
  • Mom Creators Coalition Launches with WaterWipes® as Official Founding Sponsor
  • PandaGuarantee Launches Rent Guarantor Service in New York City
  • The $112M Marketing Lesson Joe Whyte Learned: Why 'More Traffic' Is the Biggest Lie in Digital Marketing
  • Daniel Kaufman Expands Kaufman & Company Real Estate Platform With New Acquisitions, AI-Driven Industrial Development and Nationwide Growth Initiative
  • Bethany Nikitenko Elected Board Vice President of Philadelphia VIP
  • purelyIV Launches Lab Testing Services in Metro Detroit
  • On the 296th Anniversary of the Ceremony That Made His Ancestor Emperor, a Cherokee Descendant Publishes the Novel That Restores Him
  • Burkentine Builders Breaks Ground on Their 100,000-Square-Foot Warehouse in Shippensburg, PA
  • NRx Pharmaceuticals Could Be on the Verge of a Breakout Year as AI, FDA Catalysts, and Mental Health Demand Converge
  • Pine Creek Rail Trail Named Pennsylvania's 2026 Trail of the Year
  • DC Accounting Firm Offers Free Business CRM to Small Business Clients Alongside Weekly Bookkeeping Model
  • CCHR: Psychiatric Drugs Fuel Rising Death Toll: National Adverse Drug Event Awareness Day Confronts America's Medication Crisis
  • Explosive $10 Billion Counter-Drone Market with AI-Powered Defense Ecosystem: ZenaTech, Inc. (N A S D A Q: ZENA)

Popular on PennZone

  • Actress/Model Raelia Lewis Building a Powerful Name in Entertainment and Fashion
  • New Book Warring From the Standpoint of the Throne Room Calls Believers to Pray From Victory
  • Conexwest: Shipping Containers Are Powering the Next Generation of Bitcoin Mining Infrastructure
  • Claude Riveloux Review 2026: How the $10B Fund Manager Dispels 'Scam' Rumors Through Education
  • Quadcode Acquires Significant Stake in Game 7, LLC - The Parent Company for FPFX Tech and PropAccount.com
  • Pure Energy Electrical Services, LLC Announces Strong Start to 2026, Reinforcing Customer-First Electrical Service Across Northeast Florida
  • Jack and Sage Acquires Sustainable Apparel Brand Kastlfel, Expanding Premium Logo Wear Across National Parks and Ski Resorts
  • Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
  • Bent Danholm Named "Top Luxury Real Estate Leader" in Modern Luxury Miami
  • Pregis Expands Wind Energy Use, Advancing Progress Toward Net Zero by 2040

Similar on PennZone

  • New Research Identifies "The Busy Effect": 89% of Americans Want a Laid-Back Vacation — Only 15% Actually Achieve It
  • Just 1 in 57 Crypto Owners Globally Pay Taxes on Their Holdings, New Report Finds
  • purelyIV Launches Lab Testing Services in Metro Detroit
  • NRx Pharmaceuticals Could Be on the Verge of a Breakout Year as AI, FDA Catalysts, and Mental Health Demand Converge
  • CCHR: Psychiatric Drugs Fuel Rising Death Toll: National Adverse Drug Event Awareness Day Confronts America's Medication Crisis
  • UK Financial Ltd Tokenized LTNS 1, A $1.1 T Asset-Backed ERC-3643 Security Token with 11 On-Chain Contracts Verifying, Compliant Real-World Value
  • Homeowner Prep Announces Strategic Language Shift: Replacing "Renters" with "Future Homeowners" to Inspire Wealth-Building Mindsets
  • Over 98% of crypto owners globally don't declare taxes, new report find
  • Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI)
  • Forced Psychiatric Hospitalization Fails Vulnerable People: CCHR Urges Repeal Amid Rising U.S. Policies
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us